Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 41.7334
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.286
- MktCap 992485244666.0
- FreeCF/Share 10.0576
- PFCF 110.0231
- PE 53.9306
- Debt/Assets 0.3698
- DivYield 0.0054
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk
Published: December 10, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk (NVO) appears undervalued relative to Big Pharma peers, especially given its superior long-term growth and profitability metrics outside of recent setbacks. NVO's two-thirds market cap decline stems from a series of adverse events, some justified but many overdone, with the market ignoring positive developments. Despite recent underperformance versus Eli Lilly, NVO maintains industry-leading margins, robust cash flow, and strong growth prospects, notably with oral GLP-1 candidates.
Read More
Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
Published: December 09, 2025 by: Reuters
Sentiment: Positive
Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply chains.
Read More
Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Published: December 09, 2025 by: CNBC
Sentiment: Positive
Eli Lilly said it will spend $6 billion to build a manufacturing plant in Huntsville, Alabama, to help boost production of its closely watched experimental obesity pill, orforglipron, and other drugs. It is the third facility in a string of new planned U.S. investments by the drugmaker.
Read More
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Published: December 09, 2025 by: PRNewsWire
Sentiment: Neutral
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly's oral GLP-1, orforglipron Company plans to create 3,450 manufacturing and construction jobs at Lilly's ninth U.S. manufacturing site announced since 2020 INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Lilly declares first-quarter 2026 dividend
Published: December 08, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026.
Read More
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Carolyn Bertozzi returns to Lilly board of directors
Published: December 08, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D.
Read More
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly trades above key SMAs as strong GLP-1 demand, new drugs and pipeline momentum drive shares.
Read More
3 Large Drug Stocks to Watch as the Industry Shows Some Recovery
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.
Read More
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Published: December 03, 2025 by: PRNewsWire
Sentiment: Neutral
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded indication represents a substantial increase in the number of CLL/SLL patients who may benefit from Jaypirca and aligns with the patient population endorsed by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) INDIANAPOLIS , Dec. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) …
Read More
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.
Read More
Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.
Read More
Howard University Receives $10M Gift from Lilly Endowment to Support Efforts to Advance Over 155 Years of Black Theological Education
Published: December 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Washington, D.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Howard University has received a grant of $10 million from Lilly Endowment Inc. through its Pathways for Tomorrow Initiative. The funding will help the University's School of Divinity launch Wisdom Keepers, Hope Seekers (WKHS) — a groundbreaking alliance to solve critical challenges and transform pastoral leadership development by uniting seven historically Black theological institutions (HBTIs), including the Hampton University School of Religion, Hood Theological Seminary, Interdenominational Theological Center, Payne Theological Seminary, Virginia Union University Samuel DeWitt Proctor School of Theology, and Shaw University School of Divinity.
Read More
Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple
Published: December 02, 2025 by: 24/7 Wall Street
Sentiment: Positive
Analysts at Bernstein just reiterated an outperform rating on Apple (
Read More
Eli Lilly cuts price of Zepbound in heightened weight-loss drug competition
Published: December 01, 2025 by: Proactive Investors
Sentiment: Neutral
Eli Lilly and Co (NYSE:LLY) said on Monday it is lowering the cash prices of its weight-loss drug Zepbound, marking the latest move in a growing price battle with rival Novo Nordisk. The US pharmaceutical giant said single-dose vials of Zepbound will now be available on its direct-to-consumer platform, LillyDirect, at reduced prices.
Read More
Eli Lilly Stock in Focus After Slashing Cost of Popular Drug
Published: December 01, 2025 by: Schaeffers Research
Sentiment: Negative
Shares of Eli Lilly and Co (NYSE:LLY) are sliding into the red, down 0.8% to trade at $1,066.96 at last check, amid news the pharma giant cut prices on popular weight loss drug Zepbound.
Read More
Eli Lilly Lowers Weight-Loss Drug Zepbound Prices After Trump Deal
Published: December 01, 2025 by: Forbes
Sentiment: Positive
$1,086. That's the monthly cost of Zepbound before any discounts or rebates, according to Eli Lilly. The list price for Ozempic is just over $997 per month.
Read More
S&P 500 Gains and Losses Today: Intel Soars Amid Apple Deal Rumors; Eli Lilly Stock Slides
Published: November 28, 2025 by: Investopedia
Sentiment: Positive
A major U.S. chipmaker got a boost from speculation that it could win a new Big Tech customer, while a high-flying pharmaceutical stock reversed some of its recent gains.
Read More
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.
Read More
Eli Lilly is better at executing now than Novo Nordisk, says BMO's Evan Seigerman
Published: November 24, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO head of health care research, joins 'The Exchange' to discuss the gap between Novo Nordisk and Eli Lilly, the valuation gap between the stocks and much more.
Read More
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
Published: November 24, 2025 by: PRNewsWire
Sentiment: Neutral
Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve CLL/SLL patients – will be presented as an oral presentation Results from the Phase 3 BRUIN CLL-313 study of pirtobrutinib in patients with treatment-naïve CLL/SLL will be featured as a late-breaking oral presentation Both BRUIN CLL-314 and BRUIN CLL-313 were selected to be part of the official ASH press program INDIANAPOLIS , Nov. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the …
Read More
Eli Lilly Stock Joins $1 Trillion Club: What Is Happening?
Published: November 24, 2025 by: Forbes
Sentiment: Positive
Eli Lilly's stock (NYSE: LLY) soared nearly 50%, in the past six months, driven not only by outstanding earnings and a notable margin increase, but also by reaching a $1T market cap and excitement surrounding revolutionary GLP-1 and oral drug potentials. Let's explore the factors behind this extraordinary surge.
Read More
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.
Read More
Eli Lilly becomes first health-care company to hit $1 trillion
Published: November 21, 2025 by: Fast Company
Sentiment: Positive
Silicon Valley's giants crowd the list of the world's most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of one trillion dollars on Friday, becoming the first business in the health industry to hit that milestone.
Read More
3 Weight-Loss Drug Stocks To Consider For 2026
Published: November 21, 2025 by: Benzinga
Sentiment: Positive
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.
Read More
Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
Published: November 21, 2025 by: Reuters
Sentiment: Positive
Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Read More
Eli Lilly's Market Cap Breaks $1 Trillion After Climbing $400 Billion in 3 Months
Published: November 21, 2025 by: Barrons
Sentiment: Positive
It's the only drug company ever to have a $1 trillion capitalization value; the other U.S. companies are tech giants and Berkshire Hathaway.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000